The most extensive clinical study into liver cirrhosis ever conducted worldwide has been announced by Newcastle University, the University of Edinburgh and research-driven global biopharmaceutical company, Boehringer Ingelheim.
A new type of cell therapy to treat patients with liver scarring, or cirrhosis, shows promise of being the first medical treatment for this common and lethal condition.
Scientists have used gene editing techniques to identify and change parts of chicken DNA that could limit the spread of the bird flu virus in the animals.
A University of Edinburgh startup developing rapid cell analysis for the biopharmaceutical industry has raised £4 million to scale up market-testing of its technology platform.
Innovative technology that creates ultra-thin layers of human cells in tube-like structures could spur development of lifelike blood vessels and intestines in the lab.
Biotechnology spinout Kynos Therapeutics Ltd has announced that dosing is underway in a first in-human phase I trial of its lead drug candidate, KNS366.
What’s your next challenge? Spin in, spin out or start up?
